Technical Analysis for DCPH - Deciphera Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 14.85 | -4.75% | -0.74 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 50 DMA | Bearish | 0.00% | |
Expansion Pivot Sell Setup | Bearish Swing Setup | 0.00% | |
Below Lower BB | Weakness | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Down 4 Days in a Row | Weakness | 0.00% | |
Down 5 Days in a Row | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
20 DMA Resistance | Bearish | -4.75% | |
Outside Day | Range Expansion | -4.75% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 20 hours ago |
Down 5% | about 20 hours ago |
Down 1 ATR | about 20 hours ago |
Down 3% | about 20 hours ago |
Fell Below Lower Bollinger Band | about 20 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/01/2024
Deciphera Pharmaceuticals, Inc. Description
Deciphera Pharmaceuticals, LLC is a United-States based clinical-stage biopharmaceutical company. The Company provides treatment for cancer patients. The Company focuses on developing tumor-targeted and immuno-targeted kinase inhibitors. Its switch control inhibitor platform is engaged in producing kinase inhibitors with distinct profiles and anti-cancer effects. Its tumor-targeting therapies include DCC-2618. DCC-2618 is a pan-KIT and PDGFR alpha kinase switch control inhibitor in clinical development for the treatment of KIT and/or Platelet-derived growth factor receptor alpha-driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Its Immuno-Targeted Therapies include DCC-3014 and Rebastinib. DCC-3014 is a potent and highly-selective immunokinase inhibitor targeting colony stimulating factor receptor 1 (CSF1R). Rebastinib is a TIE2 inhibitor targeting TIE2 expressing macrophages. Rebastinib is in the clinical development stage.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immune System Drugs Clinical Development Cancer Treatment Gastrointestinal Antineoplastic Drugs Blastoma Protein Kinase Inhibitor Glioblastoma Targeted Therapy Tyrosine Kinase Receptors Glioblastoma Multiforme Platelet Mastocytosis Systemic Mastocytosis Gastrointestinal Stromal Tumor Gastrointestinal Stromal Tumors Treatment For Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 17.73 |
52 Week Low | 9.9 |
Average Volume | 556,886 |
200-Day Moving Average | 13.94 |
50-Day Moving Average | 15.36 |
20-Day Moving Average | 16.31 |
10-Day Moving Average | 16.26 |
Average True Range | 0.70 |
RSI (14) | 37.89 |
ADX | 23.67 |
+DI | 19.95 |
-DI | 25.09 |
Chandelier Exit (Long, 3 ATRs) | 15.62 |
Chandelier Exit (Short, 3 ATRs) | 16.76 |
Upper Bollinger Bands | 17.59 |
Lower Bollinger Band | 15.03 |
Percent B (%b) | -0.07 |
BandWidth | 15.68 |
MACD Line | 0.08 |
MACD Signal Line | 0.32 |
MACD Histogram | -0.2433 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 16.46 | ||||
Resistance 3 (R3) | 16.57 | 16.14 | 16.19 | ||
Resistance 2 (R2) | 16.14 | 15.73 | 16.09 | 16.10 | |
Resistance 1 (R1) | 15.50 | 15.48 | 15.29 | 15.39 | 16.01 |
Pivot Point | 15.07 | 15.07 | 14.97 | 15.02 | 15.07 |
Support 1 (S1) | 14.43 | 14.66 | 14.22 | 14.32 | 13.69 |
Support 2 (S2) | 14.00 | 14.41 | 13.95 | 13.60 | |
Support 3 (S3) | 13.36 | 14.00 | 13.51 | ||
Support 4 (S4) | 13.25 |